The vaccine could stop infections for nine years

Precise News

Recurring urinary tract infections (UTIs) can be prevented for up to nine years with an oral spray vaccine, a “breakthrough” British trial has found.
Recurrent infections develop in 20 to 30 per cent of cases and require short-term antibiotic treatment.
In both men and women with recurrent UTIs, over half (54 per cent) remained UTI-free for nine years after the vaccine, with no notable side effects reported.
Forty per cent of the trial participants reported having second doses of the vaccine after one or two years.
“Nine years after first receiving this new UTI vaccine, around half of the participants remained infection-free.
“Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe.
“Many of our participants told us that having the vaccine restored their quality of life.” The vaccine was developed by Spain-based pharmaceutical company Immunotek.
Recurrent UTIs are a substantial economic burden and the overuse of antibiotic treatments can lead to antibiotic-resistant infections.

NEUTRAL

A “breakthrough” British trial has discovered that an oral spray vaccine can prevent recurrent urinary tract infections (UTIs) for as long as nine years.

It can be especially dangerous for elderly individuals. Half of women and one in five men suffer from this excruciating bacterial infection. The need to use the restroom more frequently than usual or a burning feeling when urinating are symptoms.

Around 20 to 30 percent of cases result in recurrent infections, which call for brief antibiotic therapy. But as antibiotic-resistant infections increase, these medications are starting to lose their effectiveness.

In a lengthy trial, doctors at the Royal Berkshire Hospital in the UK asked 89 patients to squirt the vaccine with a pineapple flavor under their tongue once a day for three months. After that, the patients were monitored for a further nine years.

With no significant side effects reported, more than half (54%) of the men and women with recurrent UTIs were able to avoid getting sick for nine years after receiving the vaccination.

Throughout the cohort, the average infection-free period was 54.7 months (four and a half years); for women, it was 56.7 months, and for men, it was 44.3 months, or one year less. Upon receiving the vaccine again after a year or two, 40% of trial participants reported having additional doses.

“Before having the vaccine, all of our participants suffered from recurrent UTIs, and for many women, these can be difficult to treat,” said Dr. Bob Yang, a consultant urologist at the Royal Berkshire NHS Foundation Trust who co-led the study.

Roughly half of the individuals remained free of infections nine years after they were first administered this novel UTI vaccination.

“In general, this vaccination is safe over the long run, and the individuals in our study experienced a reduction in the frequency of milder UTIs. Drinking lots of water is the best way to treat a UTI, according to many of those who did get one.

Numerous individuals who took part in our study informed us that receiving the vaccination improved their quality of life. “.

Immunotek, a pharmaceutical company based in Spain, developed the vaccine. Water is suspended with four different bacterial species in the MV140. It can be purchased without a license in 26 different nations.

At this weekend’s European Association of Urology (EAU) Congress in Paris, the research was presented.

Before the vaccine is approved for use on the National Health Service (NHS), the updated findings are anticipated to be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).

The EAU Guidelines on Urological Infections chairman, Gernot Bonkat, stated: “These results are encouraging.”. The overuse of antibiotic treatments can result in infections that are resistant to the drugs, and recurrent UTIs have a significant financial cost.

Positive information regarding the MV140 vaccine’s long-term safety and efficacy has been found in this follow-up study.

“This vaccine is a potential breakthrough in preventing UTIs and could provide a safe and effective alternative to conventional treatments, but we also need to be realistic.”. “.

scroll to top